Interleukin-13 and interleukin-5 in induced sputum of eosinophilic bronchitis: comparison with asthma.

STUDY OBJECTIVES Experimental studies on asthma have indicated that interleukin (IL)-13 induces airway hyperreactivity (AHR). However, it remains unproven that IL-13 is responsible for AHR in asthmatic patients. Eosinophilic bronchitis (EB) shows normal airway responsiveness despite eosinophilic airway inflammation of severity similar to that of asthma. This study evaluated the role of IL-13 in asthma by comparing the sputum IL-5 and IL-13 levels in both groups. METHODS Comparisons between asthma and EB would clarify the role of IL-13 in AHR. IL-5 and IL-13 were assayed in the sputum and culture supernatants of peripheral blood mononuclear cells (PBMCs) from 22 asthmatic patients, 12 EB patients, and 11 healthy control subjects. RESULTS IL-13 levels were higher in the asthmatic patients than in the EB patients or healthy control subjects (p = 0.001). IL-5 levels were similar in the asthmatic patients and EB patients, who had significantly higher levels than those of healthy control subjects. Sputum IL-13, but not IL-5, is inversely correlated with the provocative concentration of a substance causing a 20% fall in FEV1 for methacholine in asthmatic patients (r = -0.502; p = 0.017). IL-13 production by PBMCs was significantly higher in asthmatic patients than in EB patients (p = 0.015), but the levels between EB patients and healthy control subjects was comparable. CONCLUSION The results of the present study indicate that IL-13 is related to AHR in asthmatic patients.

[1]  I. Pavord,et al.  Sputum and bronchial submucosal IL-13 expression in asthma and eosinophilic bronchitis. , 2004, The Journal of allergy and clinical immunology.

[2]  Choon-Sik Park,et al.  Development of chronic airway obstruction in patients with eosinophilic bronchitis: a prospective follow-up study. , 2004, Chest.

[3]  Choon-Sik Park,et al.  Association of Interleukin-5 and Eotaxin with Acute Exacerbation of Asthma , 2003, International Archives of Allergy and Immunology.

[4]  I. Pavord,et al.  Comparison of airway immunopathology of eosinophilic bronchitis and asthma , 2003, Thorax.

[5]  J. Stankova,et al.  CysLT1 receptor upregulation by TGF-beta and IL-13, but not IL-4, is associated with bronchial smooth muscle cell proliferation in response to LTD4 , 2003 .

[6]  J. Stankova,et al.  CysLT1 receptor upregulation by TGF-beta and IL-13 is associated with bronchial smooth muscle cell proliferation in response to LTD4. , 2003, The Journal of allergy and clinical immunology.

[7]  I. Pavord,et al.  TH2 cytokine expression in bronchoalveolar lavage fluid T lymphocytes and bronchial submucosa is a feature of asthma and eosinophilic bronchitis. , 2002, The Journal of allergy and clinical immunology.

[8]  D. Sheppard,et al.  Direct effects of interleukin-13 on epithelial cells cause airway hyperreactivity and mucus overproduction in asthma , 2002, Nature Medicine.

[9]  I. Pavord,et al.  Mast-cell infiltration of airway smooth muscle in asthma. , 2002, The New England journal of medicine.

[10]  R. Panettieri,et al.  IL-13 and IL-4 cause eotaxin release in human airway smooth muscle cells: a role for ERK. , 2002, American journal of physiology. Lung cellular and molecular physiology.

[11]  B. Ma,et al.  IL-13-Induced Chemokine Responses in the Lung: Role of CCR2 in the Pathogenesis of IL-13-Induced Inflammation and Remodeling1 , 2002, The Journal of Immunology.

[12]  D. Corry,et al.  The Th2 lymphocyte products IL-4 and IL-13 rapidly induce airway hyperresponsiveness through direct effects on resident airway cells. , 2002, American journal of respiratory cell and molecular biology.

[13]  K. Chung,et al.  Evidence for systemic rather than pulmonary effects of interleukin-5 administration in asthma , 2001, Thorax.

[14]  D. Umetsu,et al.  Critical Role for IL-13 in the Development of Allergen-Induced Airway Hyperreactivity1 , 2001, The Journal of Immunology.

[15]  K. Chung,et al.  Interleukin-5 induces CD34(+) eosinophil progenitor mobilization and eosinophil CCR3 expression in asthma. , 2001, American journal of respiratory and critical care medicine.

[16]  P. Foster,et al.  Interleukin-13 mediates airways hyperreactivity through the IL-4 receptor-alpha chain and STAT-6 independently of IL-5 and eotaxin. , 2001, American journal of respiratory cell and molecular biology.

[17]  J. Kinet,et al.  Direct effects of interleukin-13 on signaling pathways for physiological responses in cultured human airway smooth muscle cells. , 2001, American Journal of Respiratory and Critical Care Medicine.

[18]  A. Fryer,et al.  Eosinophil recruitment to the airway nerves. , 2001, The Journal of allergy and clinical immunology.

[19]  K. Chung,et al.  Effects of an interleukin-5 blocking monoclonal antibody on eosinophils, airway hyper-responsìveness, and the late asthmatic response , 2000, The Lancet.

[20]  H. Hammad,et al.  CC chemokines and interleukin-5 in bronchial lavage fluid from patients with status asthmaticus. Potential implication in eosinophil recruitment. , 2000, American journal of respiratory and critical care medicine.

[21]  P. Gibson,et al.  Interleukin-8 secretion and neutrophil recruitment accompanies induced sputum eosinophil activation in children with acute asthma. , 2000, American journal of respiratory and critical care medicine.

[22]  S. Holgate,et al.  Cytokine profiles of BAL T cells and T‐cell clones obtained from human asthmatic airways after local allergen challenge , 1999, Allergy.

[23]  L. Scott,et al.  Frequency and characterization of antigen-specific IL-4- and IL-13- producing basophils and T cells in peripheral blood of healthy and asthmatic subjects. , 1999, The Journal of allergy and clinical immunology.

[24]  R. Homer,et al.  Pulmonary expression of interleukin-13 causes inflammation, mucus hypersecretion, subepithelial fibrosis, physiologic abnormalities, and eotaxin production. , 1999, The Journal of clinical investigation.

[25]  D B Corry,et al.  Requirement for IL-13 independently of IL-4 in experimental asthma. , 1998, Science.

[26]  D D Donaldson,et al.  Interleukin-13: central mediator of allergic asthma , 1998 .

[27]  M. Jordana,et al.  Circulating, but not local lung, IL-5 is required for the development of antigen-induced airways eosinophilia. , 1998, The Journal of clinical investigation.

[28]  P. Foster,et al.  A novel T cell-regulated mechanism modulating allergen-induced airways hyperreactivity in BALB/c mice independently of IL-4 and IL-5. , 1998, Journal of immunology.

[29]  S. Durham,et al.  Elevated expression of messenger ribonucleic acid encoding IL-13 in the bronchial mucosa of atopic and nonatopic subjects with asthma. , 1997, The Journal of allergy and clinical immunology.

[30]  F. Hargreave,et al.  Indices of airway inflammation in induced sputum: reproducibility and validity of cell and fluid-phase measurements. , 1996, American journal of respiratory and critical care medicine.

[31]  L. Lichtenstein,et al.  IL-13 expression at the sites of allergen challenge in patients with asthma. , 1995, Journal of immunology.

[32]  B. Make,et al.  Standards for the diagnosis and care of patients with chronic obstructive pulmonary disease. American Thoracic Society. , 1995, American journal of respiratory and critical care medicine.

[33]  S. Durham,et al.  Predominant TH2-like bronchoalveolar T-lymphocyte population in atopic asthma. , 1992, The New England journal of medicine.

[34]  J. Denburg,et al.  Use of induced sputum cell counts to investigate airway inflammation in asthma. , 1992, Thorax.

[35]  J. Denburg,et al.  CHRONIC COUGH: EOSINOPHILIC BRONCHITIS WITHOUT ASTHMA , 1989, The Lancet.

[36]  Phillips Yy,et al.  Standards for the diagnosis and care of patients with chronic obstructive pulmonary disease (COPD) and asthma. This official statement of the American Thoracic Society was adopted by the ATS Board of Directors, November 1986. , 1987, The American review of respiratory disease.